Know Cancer

forgot password

A Prospective, Multi-Center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)

Phase 4
18 Years
85 Years
Not Enrolling
Barrett's Esophagus, High Grade Dysplasia, Low Grade Dysplasia

Thank you

Trial Information

A Prospective, Multi-Center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)

The study will consist of an estimated 200 subjects with HGD or LGD within BE who are deemed
inoperable or refuse standard surgical treatment. A maximum of 20 investigational sites
will participate with a maximum of ten subjects per site.

Inclusion Criteria:

- Karnofsky performance status of 50-100%

- Life expectancy greater than 5 years

- Hematopoietic, Hepatic and Renal lab clearance

- Previous endoscopy with histological confirmation of LGD or HGD within BE

- For Group 2, deemed inoperable based on the following criteria: co-morbid
conditions such as severe heart, lung, kidney or liver disease; or refusal of
surgical intervention after a thorough unbiased discussion of surgery.

- For Group 2, endoscopic ultrasound (EUS) evaluation demonstrating no evidence of
invasion or metastatic lymph node involvement (T0N0M0 by EUS).

Exclusion Criteria:

- Pregnant, not practicing adequate contraception, intending to become pregnant, or
lactating at any time during the study (approximately 2 years).

- Esophageal stricture preventing passage of endoscope or catheter.

- Active esophagitis

- EMR performed less than 8 weeks prior to CSA treatment.

- EMR performed on greater than 90% circumference of any area of the esophagus.

- Any previous esophageal surgery, except fundoplication without complications.

- Known history of unresolved drug or alcohol dependency that would limit ability to
comprehend or follow instructions related to informed consent, post-treatment
instructions, or follow-up guidelines.

- Concurrent enrollment in an investigational drug or device trial that clinically
interferes with the LCS Dysplasia endpoints.

- Psychiatric or other illness deemed by the investigator as an inability to comply
with this protocol.

- Medically unfit or other contraindication to tolerate upper endoscopy.

- Inability to tolerate therapy with a proton pump inhibitor (PPI).

- Refusal or inability to give consent.

- Other active malignancy (except nonmelanoma skin cancer or another cancer for which
patient is deemed disease-free).

- Concurrent chemotherapy.

- Prior radiation therapy which involved the esophagus.

- Prior adenocarcinoma involving the esophagus or stomach.

- Prior or concurrent ablation therapy including, but not limited to, photodynamic
therapy, multipolar electro coagulation, argon plasma coagulation, laser treatment,
radio frequency, etc.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.

Outcome Time Frame:

2 years post treatment

Safety Issue:


Principal Investigator

Bruce Greenwald, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Maryland


United States: Institutional Review Board

Study ID:




Start Date:

September 2007

Completion Date:

September 2011

Related Keywords:

  • Barrett's Esophagus
  • High Grade Dysplasia
  • Low Grade Dysplasia
  • Low Grade Dysplasia
  • High Grade Dysplasia
  • Barrett's Esophagus
  • Cryospray ablation
  • ICE
  • Cryotherapy
  • Cryo
  • CryoSpray
  • Barrett Esophagus
  • Hyperplasia



Cleveland Clinic Foundation Cleveland, Ohio  44195
Rhode Island Hospital Providence, Rhode Island  02903
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Boston Medical Center Boston, Massachusetts  02118
University of Pittsburgh Medical Center Pittsburgh, Pennsylvania  15213
Baylor University Waco, Texas  
Duke University Medical Center Durham, North Carolina  27710
H. Lee Moffitt Cancer Center Tampa, Florida  33612
Thomas Jefferson University Hospital Philadelphia, Pennsylvania  19131
University of Maryland Medical Center Baltimore, Maryland  21201-1595
Norwalk Hospital Norwalk, Connecticut  06856
Columbia University Medical Center New York, New York  10032
University of California -Irvine Orange, California  92868
Hoboken Universtiy Medical Center Hoboken, New Jersey  07030
Universtiy of North Carloina at Chapel Hill Chapel Hill, North Carolina  27599
Lancaster Reginal Medical Center Lancaster, Pennsylvania  17604